Economic Burden of Renal Cell Carcinoma in the US: Part II - An Updated Analysis

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.29, Iss.4, 2011-04, pp. : 331-341

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Burden of Renal Cell Carcinoma: Part I - An Updated Review

By Shih Ya-Chen T.

PharmacoEconomics, Vol. 29, Iss. 4, 2011-04 ,pp. : 315-329

Adis International

Access to resources Recommend Favorite

Economic burden of osteoarthritis in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 596, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Economic burden of psoriasis in the US

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 375, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

En Bloc Adrenalectomy as Part of Radical Nephrectomy for Renal Cell Carcinoma. Is it Justified?

By Adshead J.M. Livni N. Christmas T.J.

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 95-97

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka Heilbrun Lance Shields Anthony Lawhorn-Crews Jawana Baranowski Karen Smith Daryn Flaherty Lawrence

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite